Pharming Group NV reported declines across all financial indicators in 2021 owing to the impact of Covid-19 on healthcare activity in the US and impairments of tangible and intangible assets. At the same time, it invested in future growth by way of an in-licensing deal for a candidate gene therapy, OTL-15. It also brought leniolisib, a drug for a rare immunodeficiency disease, into late-stage development. Revenue, driven by sales of Ruconest, its lead product for the treatment of acute hereditary angioedema (HAE), was $198.9 million for the year, down by 6%.
